Compare Cenovus Energy Inc (CVE) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Enveric Biosciences Inc — how do they compare? Cenovus Energy Inc trades at $31.49 (market cap $56.66B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Cenovus Energy Inc is far larger — about 8469.4× Enveric Biosciences Inc's market cap, and Cenovus Energy Inc pays a 2.03% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Enveric Biosciences Inc for 14 Days on average.
| CVE | ENVB | |
|---|---|---|
Market Cap | $56.66B | $6.69M |
Volume | 7,667,753 | 41,141 |
Sector | Energy | Health |
52-Week High | $33.92 | $10.80 |
52-Week Low | $15.85 | $1.27 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | $62.61B | -$1.60M |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 0.8% today, with a bearish technical signal but strong fundamentals including a P/E of 12.14 and net income margin of 11.48%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 met estimates. Cash flow from operations remains robust at $8.23B in 2025, though net cash flow was negative due to high capital expenditures. The stock is near its pivot point of $31, with support at $30 and resistance at $32.
Outlook: CVE offers value with attractive valuation ratios and solid profitability, but faces headwinds from volatile oil prices and capital-intensive operations. Analyst consensus is mixed with 40.7% buy ratings, suggesting cautious optimism amid energy sector uncertainty.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
